DreamPharm Products:
Lutein-20||Herbs for headache, fever, and migraine ||
Milk thistle||Saw palmetto||
Triple B Super Vision||Garlic, Ginger, and Grapeseed Extract||
Ginseng and Ginkgo||Hair Million||
DHEA||Coenzyme Q10||
Sleep Aid herbal formula - natural sleep aid||Herbal Breath - herbs for bad breath problems.||
Weight loss herbal formula||Ginkgo biloba||
Colon cleansing, Laxative for constipation relief, laxative, and colon cleansing||ViaVita, Lecithin for healthy liver
Interferon research abs 1 ||
Hemoglobin research abs ||
Stem cell research abs ||
Nucleic acid research abs ||
Herpes research abs ||
Bronchitis research abs ||
Schizophrenia research abs ||
Tuberculosis research abs ||
Pneumonia research abs ||
Constipation research abs ||
Laxative research abs
Eur J Oncol Nurs. 2001 Mar;5(1):18-25.
Evidence-based management of constipation in the oncology patient.
Smith S.
Young Oncology Unit, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 4 BX, UK
Constipation is suffered by over 50% of cancer patients and is regarded as one of the most distressing symptoms causing both physical and emotional distress. A need to treat constipation is often due to a failure to prevent it. There is little literature in this area and research based on clinical trials as to best treatment is virtually non-existent. It is suggested that many health-care professionals dismiss constipation as a relatively trivial problem, resulting in a lack of attention to the subject. There is a lack of consensus on the definition of constipation and confusion regarding effective methods for prevention and treatment. It could be argued that health-care professionals are more intent on monitoring the direct effects rather than the secondary effects of treatment. Since constipation is largely preventable, there is a need to highlight the importance of prevention in addition to establishing effective treatment guidelines. Oncology nurses are in an ideal position to identify cancer patients in a high-risk category and utilize preventive strategies. The study described has led to the development of evidence-based drug guidelines to be used in the prevention of constipation and acute/chronic constipation to ensure that patients receive the best treatment possible.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12849044&dopt=Abstract [PubMed]
Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:59-65.
Thalidomide therapy for renal cell carcinoma.
Amato RJ.
Scott Department of Urology, Baylor College of Medicine, 6560 Fannin, Suite 2100, 77030, Houston, TX, USA
PURPOSE: To review the use of thalidomide as a therapeutic option for patients with metastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: Studies of thalidomide alone or in combination with immunotherapy or chemotherapy were identified. The clinical benefit of thalidomide was assessed on the basis of objective response (complete and partial) and stable disease rates. RESULTS: Single-agent thalidomide was evaluated in nine phase II studies, producing partial responses in a median of 7% of patients (range: 0-17%) and stable disease in a median of 31% of patients. On average, 40-45% of patients derived benefit from thalidomide. Common toxicities included constipation, lethargy, and with prolonged therapy, neuropathy. Four studies reported deep vein thrombosis and/or pulmonary embolism at rates ranging from 3 to 23%. On the basis of these findings, phase I/II studies of thalidomide in combination with interleukin-2 (IL-2), interferon (IFN), or chemotherapy have been conducted. Although some of these early combination regimens were limited by toxicity, promising findings have been seen with thalidomide/IL-2 and thalidomide/IFN/capecitabine. A phase III trial of IFN versus IFN/thalidomide is nearing completion. CONCLUSION: Thalidomide is active in metastatic RCC, but additional experience with thalidomide-based combinations is needed to better define how this agent should be used in the management of this malignancy.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12850528&dopt=Abstract [PubMed - in process]
Int Urogynecol J Pelvic Floor Dysfunct. 2003 Jun;14(2):128-32. Epub 2003 Mar 12.
The association of obstructive defecation, lower urinary tract dysfunction and the benign joint hypermobility syndrome: a case-control study.
Manning J, Korda A, Benness C, Solomon M.
Urogynaecology Unit, Royal Prince Alfred Hospital, Australia.
It has been suggested that, apart from obstetric trauma, chronic straining at stool may also result in pudendal nerve damage, contributing to the etiology of genuine stress incontinence (GSI). The benign joint hypermobility syndrome (BJHS) has been associated with rectal as well as uterovaginal prolapse, suggesting that connective tissue abnormalities may also be implicated. This study was undertaken in order to further investigate whether - and if so, why - an association may exist between symptoms of obstructive defecation, lifetime constipation, chronic heavy lifting and lower urinary tract (LUT) dysfunction. Cases were female patients referred for urodynamic assessment with symptoms of LUT dysfunction. Controls were age-, sex- and postcode-matched community controls. Both cases and controls were assessed using a detailed questionnaire that also asked about symptoms of BJHS. Cases were also divided into their urodynamic classification of LUT dysfunction. All symptoms of obstructive defecation (52.3% vs 33.6%, P=0.00003), as well as chronic straining at stool (38.6% vs 23.4%, P=0.0005), were significantly more common in women with LUT dysfunction than in community controls. BJHS, chronic heavy lifting and a history of uterovaginal prolapse were significantly associated with patients with LUT and obstructive defecation compared to those with LUT dysfunction alone. Overall, symptoms of obstructed defecation were not more prevalent in any one urodynamic diagnostic group than in others. However, childhood constipation and current constipation were significantly more prevalent in women with voiding dysfunction than in those with other urodynamic diagnoses (16.7% vs 5.5%, P = 0.0030 and 13.0% vs 5.7%, P = 0.017). We concluded that women with LUT dysfunction are more likely to have symptoms of obstructive defecation than are community controls. Connective tissue disorders such as BJHS may be an important factor in this association.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12851757&dopt=Abstract [PubMed - in process]
Vitamins, amino acids, oils for topical application, and prescription medications...
There are a number of approaches to hair loss problems.
Hair Million is an herbal alternative. It is a formula made of traditional, edible herbs
and has been anecdotally demonstrated the efficacy to ward off hair loss
problems.
There is no singular medical or alternative cure for hair loss since the
biology of hair growth is a highly complicated phenomenon.
It is unknown how Hair Million stops hair loss,
and promotes hair restoration.
The advantages of Hair Million over other approaches are, firstly, Hair Million is comparatively inexpensive,
and secondly, it is made only of traditionally used safe and healthy herbs that promote hair growth
according to Chinese pharmacopoeia. In addition, Hair Million is cardiotonic, meaning that Hair Million consists of herbs
that strengthens your heart, according to Chinese medicine. There is an interesting research paper which correlates baldness
to heart diseases: people with alopecia or hair loss
problems are significantly more likely to develop heart attacks.
DHEA is a natural hormone, and it is produced in our body by the adrenal glands.
DHEA has been suggested to provide numerous potential benefits. DHEA (or dehydroepiandrosterone) is converted into androgens (male hormones)
or estrogens (female hormones) in the cells.
DreamPharm Online Healthy Supplements ||
Lutein ||
Progesterone Cream ||
Natural herbal formula for hair loss problems ||